Latest Headlines

  1. Medimaps Group To Unveil TBS Reveal – Opportunistic Screening AI Software On X-ray – At RSNA 12/1/2025

    Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, today announced the first live presentations of its new software TBS Reveal* at the prestigious Radiological Society of North America (RSNA) 2025 Annual Meeting, taking place in Chicago, IL, from November 30 to December 4.

  2. L&T Technology Services Transforms Respiratory Diagnostics With NVIDIA AI-Powered Digital Twin Technology 12/1/2025

    L&T Technology Services, a global leader in AI, Digital & R&D Consulting Services, today announced the development of a next-gen AI-powered digital twin platform for respiratory diagnostics and lung navigation.

  3. Tianlong Strengthens Transfusion Safety With Innovative Blood Screening Solutions On World AIDS Day 2025 11/28/2025

    On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution.

  4. Leica Biosystems And L7 Informatics Announce Strategic Partnership To Develop The Next Generation Of Informatics Solutions To Improve Operational Efficiency In Pathology Labs 11/24/2025

    Leica Biosystems, a global leader in cancer diagnostics and digital pathology, together with L7 Informatics, a pioneer in data unification and workflow orchestration for life sciences, announce a strategic partnership to advance leading pathology informatics.

  5. Philips Launches Next-Generation Web-Based Diagnostic Viewer For Fast, Secure Imaging Data Access Anywhere 11/24/2025

    Royal Philips a global leader in health technology, today announced the launch of Philips Image Management 15, the next generation of Philips Vue PACS, including a zero-footprint, web diagnostic viewer [1] that transforms how radiologists access and interpret medical images.

  6. Oasis Diagnostics And Oludent Health Announce Major Strategic Partnership To Expand Saliva-Based Diagnostics 11/24/2025

    Oasis Diagnostics Corporation (USA), a global leader in non-invasive saliva collection and testing technologies, and Oludent Health International FZC (UAE), a fast-growing molecular diagnostics and telehealth provider, today announced a strategic project partnership designed to bring scalable, accessible diagnostic solutions to emerging markets across Africa, the Middle East, and Southeast Asia.

  7. ABL Diagnostics Announces Partnership With seqWell To Advance NGS Library Preparation For Infectious Disease 11/24/2025

    ABL Diagnostics a Euronext-listed leader in molecular diagnostics, is pleased to announce a new partnership with seqWell to develop, validate, license, and commercialize an advanced library preparation solution derived from seqWell’s ExpressPlex platform to expand market share and target new NGS markets.

  8. Lunit And Labcorp Announce Strategic Collaboration To Advance AI-Powered Digital Pathology Research 11/20/2025

    Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

  9. Innovative Lab Services Broadens Capabilities Through Acquisition Of Overbrook 11/20/2025

    Innovative Lab Services LLC (“ILS”), a leading provider of laboratory maintenance and management solutions, today announced the acquisition of Overbrook Scientific (“Overbrook”), a Boston-based company specializing in equipment planning, laboratory relocations, asset management, and multi-vendor instrument maintenance.

  10. Thermo Fisher Scientific's Oncomine Dx Target Test Receives FDA Approval As A Companion Diagnostic To Identify Patients Eligible For Newest Targeted Therapy For Non-Small Cell Lung Cancer 11/20/2025

    Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer.